0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessTatsuya Yamashita, Yoshitaka Inaba, Masafumi Ikeda, Miyuki Sone, K. Yamakado, Hideyuki Nishiofuku, Kazuhiro Tsuchiya, Toshifumi Tada, Yozo Sato, Takahiro Kodama, Teiji Kuzuya, Sadahisa Ogasawara, Makoto Ueno, Hideki Iwamoto, Michihisa Moriguchi, Kazuomi Ueshima, Yoshihisa Kodama, Tetsuo Takehara, Takayuki Hamano, Masatoshi Kudo (2023). 205TiP IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.784.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2023
Authors
20
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.annonc.2023.10.784
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
